ADAM9 drives PD-L1 shedding via IL-6 suppression and exploring therapeutic role of Bufalin treatment in hepatocellular carcinoma
Abstract The treatment landscape for advanced hepatocellular carcinoma (HCC) has changed significantly with the recent introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as those for programmed cell death ligand 1 (PD-L1). However, the heterogeneous response to ICI...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer
2025-10-01
|
| Reeks: | Discover Oncology |
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1007/s12672-025-03522-y |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|